OSCR logo

Oscar Health Inc. OSCR

UnknownUnknownN/A📅 Scored March 14, 2026
Price at analysis: $12.17
Crucible Score
49.4
C-
Quality × Value Composite
KQI — Quality
40.9
D+
Fundamental Quality Index
KVI — Value
59.8
C
Valuation Attractiveness Index
Crucible Verdict — OSCR

Oscar Health Inc. (OSCR) presents a stark quality-value divide, with poor financial metrics (19 score) dragging down an otherwise mediocre profile despite reasonable growth prospects and competitive positioning. The 35% upside to fair value reflects the market's skepticism about OSCR's path to profitability in the competitive health insurance landscape. Execution on financial discipline will determine whether this discount closes.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality⚠
18.7
Growth Profile⚠
47.1
Moat Durability⚠
51.6
Management Effectiveness
51.9
Diversification & Resilience⚠
28.0
Market Position
34.0
Weakest dimension: Financial Quality (18.7)

◆ KVI Value Dimensions

DCF Margin of Safety
68.6
FCF Yield & Cash Returns
72.0
Relative Valuation
63.5
Growth-Adjusted Value
35.0
Historical Valuation
50.0
Macro Context
23.0

◆ DCF Valuation Scenarios

Bear Case
$7.82
Base Case
$16.45
Bull Case
$28.93
Price at Analysis
$12.17
ScenarioFair ValueRev CAGR (5yr)Terminal MarginWACC
🔴 Bear$7.8212.0%2.0%15.8%
🟢 Base$16.4518.0%3.0%14.9%
🟢 Bull$28.9322.0%4.0%13.9%
Key Assumptions: OSCR is a high-growth health insurer with revenue growing from ~$1.9B to ~$11.7B over 5 years (~44% CAGR) but only recently approaching profitability with EBITDA margins turning slightly positive. WACC is elevated at ~15% reflecting beta of 1.90 and 5.5% ERP. Operating margins are assumed to gradually expand from near-zero to 2-4% at terminal year given the low-margin nature of health insurance, with capex remaining minimal at ~0.3% of revenue. FCF generation has been volatile and heavily influenced by float/working capital timing in the insurance model.

◆ Financial Snapshot

Profitability

Gross Margin14.4%
Operating Margin-3.4%
Net Margin-3.8%
ROIC-21.1%
ROE-18.1%

Balance Sheet

Balance SheetCR: 0.95
Cash Conversion
Capital IntensityCapex/Rev: 0.3%
Altman Z-Score1.24 (Distress)
Piotroski F-Score3/9 (Weak)

Growth

Revenue CAGR-65.1% CAGR (suspect)
Earnings CAGRInsufficient data
Growth ConsistencyCV: 1.82
Segment BreadthNo data
Quarterly TrendRev→+17%, Margin↓↓, Exp↓
Earnings CredibilityTends to Beat

◆ Analyst Consensus & Leadership

Leadership & Governance

CEO Ownership23.2%
Compensation34% performance-based
Insider ActivitySelling
Earnings Beat Rate67% (14/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+
MethodologyAll ScoresCrucible BriefsPerformance@KaladinCI

Analysis conducted March 14, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.

© 2026 Kaladin Capital Intelligence — Conviction Through Scrutiny